Table 1.
Baseline Patient Characteristics
| Characteristic | MWA Group | Non-MWA Group | P Value |
|---|---|---|---|
| (n=77) | (n=75) | ||
| Age (Year) | 0.704 | ||
| Mean±SD | 54.22±12.21 | 54.92±13.31 | |
| Range | 22–79 | 27–78 | |
| Gender | 0.386 | ||
| Male | 70(90.9) | 66(88.0) | |
| Female | 7(9.1) | 9(12.0) | |
| ECOG (Score) | 0.684 | ||
| 0 | 16(20.8) | 10(13.3) | |
| 1 | 39(50.6) | 34(45.3) | |
| 2 | 22(28.6) | 31(41.4) | |
| Etiology | 0.121 | ||
| HBV/HCV | 58(75.3) | 60(80.0) | |
| Other | 19(24.7) | 15(20.0) | |
| Tumor Size (cm) | |||
| Mean±SD | 5.95±2.05 | 6.36±2.11 | 0.234 |
| Range | 3.7–10.0 | 4.1–10.0 | |
| No. of Tumors | 0.498 | ||
| Single | 33(42.9) | 23(30.7) | |
| Multiple | 44(57.1) | 52(69.3) | |
| PVTT | 46(59.8) | 49(65.3) | 0.194 |
| Main portal vein | 0 | 0 | — |
| First-order PV branch | 21(27.3) | 27(36.0) | 0.247 |
| Second- or lower-order PV branches | 25(32.5) | 22(29.3) | 0.676 |
| AFP Level (ng/mL) | |||
| ≤ 400 | 38(49.4) | 43(57.3) | 0.163 |
| > 400 | 39(50.6) | 32(42.7) | |
| Child–Pugh Class | |||
| A | 53(68.8) | 48(64.0) | 0.832 |
| B | 24(31.2) | 27(36.0) | |
| BCLC Stage C | 77(100) | 75(100) | — |
| TACE Sessions | |||
| Mean±SD | 3.29±1.38 | 2.88±1.15 | 0.051 |
| Range | 1–8 | 1–5 | |
| Duration of Sorafenib (Month) | |||
| Mean±SD | 14.19±9.11 | 11.85±8.21 | 0.099 |
| Range | 3–39 | 3–28 |
Note: Unless otherwise indicated, data are the number of patients, with percentage in parentheses.
Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; PV, portal vein; PVTT, portal vein tumor thrombosis; AFP, a-fetoprotein; HCV, hepatitis C virus; cm, centimeter; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; S, sorafenib; MWA, microwave ablation.